First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
RCT (n=719) found overall survival was significantly longer in group assigned to nivolumab plus ipilimumab with chemotherapy vs. chemotherapy alone (median 14.1 months [95% CI 13.2–16.2] vs. 10.7 months [9.5–12.4]; hazard ratio 0.69 [96.71% CI 0.55–0.87]; p=0.00065).
Source:
The Lancet Oncology
SPS commentary:
Authors’ of a related commentary highlight that the control group in CheckMate 9LA did not represent the current standard of care in patients with all levels of PD-L1 expression, which has been identified as the combination of chemotherapy plus pembrolizumab in KEYNOTE-189 and KEYNOTE-407 trials. From this perspective, authors’ state the combination of nivolumab plus ipilimumab with a short course of chemotherapy offers a great opportunity to broaden treatment options for this patient population; however, as yet there is insufficient robust data to identify the optimal treatment of the various approved immune-based combinations for the first-line treatment of patients with metastatic non-small-cell lung cancer.